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A new human breast cancer cell line, KPL-3C, secretes parathyroid
hormone-related protein and produces tumours associated with
microcalcifications in nude mice
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Summary Parathyroid hormone-related protein (PTHrP) is the main cause of humoral hypercalcaemia of
malignancy (HHM). We recently established a new human breast cancer cell line, designated KPL-3C, from the
malignant effusion of a breast cancer patient with HHM. Morphological, cytogenetic and immunohistochem-
ical analyses indicated that the cell line is derived from human breast cancer. The KPL-3C cells stably secrete
immunoreactive PTHrP measured by a two-site immunoradiometric assay, possess both oestrogen and
progesterone receptors and are tumorigenic in female nude mice. The addition of phorbol-12-myristate-13-
acetate to the medium significantly increased PTHrP secretion from the cells. In contrast, hydrocortisone,
medroxyprogesterone acetate and 22-oxacalcitriol decreased PTHrP secretion in a dose-dependent manner.
Unexpectedly, a number of microcalcifications were observed in the transplanted tumours. Radiographical
examination indicated that the microcalcifications in the tumours are very similar to those commonly observed
in human breast cancer. These findings suggest that this KPL-3C cell line may be useful for studying the
regulatory mechanisms of PTHrP secretion and the mechanisms that lead to the deposition of
microcalcifications in breast cancer.
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Parathyroid hormone-related protein (PTHrP) is a recently
discovered protein sharing strong homology with parathyroid
hormone in the N-terminal amino acid sequence as well as
biological activity (Suva et al., 1987; Mangin et al., 1988).
This protein was originally isolated from human malignant
tumours associated with humoral hypercalcaemia. A number
of clinical studies indicate that PTHrP is the main cause of
HHM (Burtis et al., 1990; Grill et al., 1991; Ratcliffe et al.,
1992). In other words, tumour-derived PTHrP acts as a
circulating hormone like parathyroid hormone and induces
hypercalcaemia. Recently, a series of studies has indicated
that PTHrP is commonly expressed in breast cancer and that
a higher expression of PTHrP may induce bone metastasis
(Southby et al., 1990; Powell et al., 1991; Bundred et al.,
1992; Vargus et al., 1992; Bouizar et al., 1993; Kohno et al.,
1994a; Kohno et al., 1994b). It is conceivable that the PTHrP
secreted by breast cancer cells, which exist in bone marrow,
may act as a paracrine effector on osteoclasts, resulting in
osteolytic involvement. These findings suggest that the
PTHrP secreted by malignant tumours may act as a
hormone or paracrine effector in different pathological
situations.
Microcalcifications are commonly observed in breast
cancer tissues (Snyder and Rosen, 1971). However, the
mechanisms that lead to their deposition in the tissues are
still poorly understood. Recently, the expression of bone
sialoprotein, a bone matrix protein, in breast cancer cells was
demonstrated in breast cancer tissues by immunohistochem-
istry. Its higher expression was suggested to correlate
positively with the deposition of microcalcifications in the
tissues (Bellahcene et al., 1994). Another study demonstrated
a positive relationship between the expression of PTHrP in
breast cancer cells and the deposition of microcalcifications in
breast cancer tissues, suggesting that the PTHrP secreted by
breast cancer cells may alter a local metabolism of calcium
and may lead to the deposition of calcified precipitates
(Kanbara et al., 1993).
We recently established a new human breast cancer cell
line, designated KPL-3C, which is derived from the
malignant effusion of a breast cancer patient with HHM.
Preliminary characterisation of this cell line and the
inhibitory effect of steroid hormones on PTHrP secretion
are described in the present paper.
Materials and methods
The clinical course of the patient
A 37-year-old Japanese woman with an invasive ductal
carcinoma of the breast underwent a radical mastectomy in
October 1990. Local recurrence appeared in July 1991. She
received combined treatment including chemoendocrine
therapy and radiotherapy to the local recurrent sites
between October 1991 and August 1993. Liver metastasis
and bilateral pleural effusion were detected at the beginning
of September 1993. Then, hypercalcaemia suddenly occurred
without any symptoms suggesting bone metastases. Severe
hypercalcaemia up to 13.6 mg 100 ml-' (the normal range
of our hospital: 8.0-10.0 mg 100 ml-') and a low serum
level of inorganic phosphorus down to 1.8 mg 100 ml-' (the
normal range: 2.8-5.2 mg 100 ml-') were observed. At the
same time, a high blood level of C-terminal PTHrP
(287 pmol 11, the normal range: less than 10 pmol 1-1)
measured by a radioimmunoassay (SRL Co., Tokyo, Japan)
was also detected. These findings suggest that this
hypercalcaemia is humoral and may be caused by a high
blood level of PTHrP secreted by recurrent breast cancer.
Thoracentesis was performed for cytological examination
and to decrease the volume of pleural fluid. Cytological
examination disclosed atypical epithelial cells in the pleural
effusion. The serum calcium level would have gradually
increased and the patient died of breast cancer at the end of
September 1993.
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Cell culture
A heparinised 50 ml of the pleural effusion was centrifugated
at 150 g for 10 min. The cell pellet was resuspended and
plated in T-25 flasks (Corning Japan, Tokyo, Japan)
containing RPMI-1640 medium (GIBCO BRL, Bethesda,
MD, USA) supplemented with 10% fetal bovine serum (FBS,
ICN Biochemicals Japan, Osaka, Japan). Serial passages
using 0.05% trypsin (Difco Lab., Detroit, MI, USA) and
0.02% EDTA in phosphate-buffered saline (PBS) were done
once in 1 or 2 weeks. Atypical epithelial cells tended to
produce colonies. To isolate the epithelial cells from
surrounding stromal cells, culture cells were dispersed by
the trypsin solution at room temperature for a few minutes,
and round-shaped sterile nitrocellulose filter papers (approxi-
mately 2 mm in diameter) were put on the colonies. Then, the
papers to which the colonies attached were picked up with
forceps and immersed in the medium. One of the fastest-
growing colonies was cultured and passed more than 50 times
for over 2 years. The epithelial cells derived from this colony
were designated as KPL-3C cells. Since the cytogenetic
analysis described below indicated that the cells have a
single peak of the chromosomal number and nine common
chromosomal aberrations, we have not attempted to subclone
them.
Morphological analysis
Haematoxylin and eosin staining of paraffin-embedded
specimens was performed using the conventional method.
Microcalcifications were defined as small basophilic deposits
with a laminated configuration. Microphotographs were
obtained with an Olympus AH-2 microscope (Olympus,
Tokyo, Japan). The cultured KPL-3C cells in the T-25 flasks
were observed and phase-contrast microphotographs were
taken with an inverted Nikon Diaphot-TMD microscope
(Nikon, Tokyo, Japan). For transmission electron micro-
scopy, the transplanted KPL-3C tumours were resected,
minced into specimens 1 mm in size and fixed with 2.5%
glutaraldehyde (Sigma Chem. Co., St Louis, MO, USA) in
PBS for 2 h at 4°C. After washing with PBS, the blocks
were post-fixed with 1% osmium tetroxide in 0.1 M
cacodylate buffer and embedded in epoxy resin. These
blocks were cut into thin sections with a SuperNova
ultracutter (Reichert-Jung, Vienna, Austria) with a diamond
knife, stained with uranyl acetate and lead citrate and
examined with a Hitachi H-7100 electron microscope
(Hitachi Electronics Co., Tokyo, Japan). For immunohisto-
chemical study, paraffin sections of the tumour samples were
dewaxed in xylene, hydrated with PBS, treated with
hydrogen peroxide for elimination of endogenous perox-
idase and then processed by the immunoperoxidase
procedure. Anti-human cytokeratin recognising subtype
numbers 10, 14, 15, 16 and 19 (Moll et al., 1982) (Milab
Co., Tokyo, Japan), anti-carcinoembryonic antigen (Milab
Co.), anti-CA 15-3 (Turner Co., Tokyo, Japan), anti-EMA
(Dako Corp., Carpinteria, CA, USA), anti-vimentin (Dako
Corp.), anti-c-erbB2 oncoprotein (Triton Bioscience Inc.,
Alameda, CA, USA) and anti-PTHrP (1-34), which is
kindly provided by Dr Shohei Kitazawa, Kobe University
School of Medicine (Kitazawa et al., 1991), antibodies were
used as the first antibodies. Control experiments were
performed by substituting normal serum for the first
antibodies. The reaction was visualised by streptavidin-
biotin (Nichirei, Tokyo, Japan) techniques following the
manufacturer's recommendations. The sections were counter-
stained with methyl green.
Chromosomal analysis
Cytogenetic analysis was performed when the cell line had
been passed 8 or 35 times. Semi-confluent cells were exposed
to 0.1 jIg ml-' colcemid for 4 h and then detached with the
trypsin solution. A hypotonic solution of 0.075 M potassium
chloride was added, and then the cells were fixed with 3:1
methanol-acetic acid and stained conventionally with
Giemsa.
Oestrogen receptor (ER) and progesterone receptor (PgR)
analysis
ER and PgR in the pellet of the cultured KPL-3C cells or in
the tumours transplanted into nude mice were measured by
an enzyme immunoassay using the ER-EIA and PgR-EIA
kits (Dinabot Inc., Tokyo, Japan) following the manufac-
turer's recommendations.
Oncogene amplification
Total cellular DNA from KPL-3C cells was extracted by a
conventional phenol-chloroform method. DNA dot-blot
hybridisation was performed as previously described
(Kurebayashi et al., 1995). Briefly, DNA samples were
spotted onto Hybond N nylon sheets (Amersham, Arlington
Heights, IL, USA) using a Hybri-dot blotting manifold
(BRL, Bethesda, MD, USA). Then the sheets were hybridised
with 32P-labelled specific DNA probes and exposed to X-ray
films. Hybridisation signals were analysed with a BSA2000
bioimaging analyser (Fuji Film, Tokyo, Japan). The degree of
amplification was estimated by a comparison with the
radioactivity of placental DNA on the same membrane.
The actin probe was used as an internal control. The DNA
probes were a 1.6 kb EcoRI fragment of human erbB-2, a
3.7 kb SacI fragment of H-ras and a 1.1 kb cDNA of K-ras.
All DNA probes were obtained from Otsuka Pharmaceutical
(Tokushima, Japan).
Cell growth in vitro and in vivo
Approximately 1 x 105 cells per well were plated in 12-well
plates (SB Medical, Tokyo, Japan) and grown in RPMI-1640
medium supplemented with 10% FBS for 2 weeks at 37°C in
a 5% carbon dioxide atmosphere. Triplicate wells were
trypsinised every other day and the viable cells were counted
in a haemocytometer using trypan blue exclusion. The
tumour doubling time was estimated from the linear portion
of the growth curve. To investigate the tumorigenicity of the
KPL-3C cells, semi-confluent KPL-3C cells were trypsinised
and harvested. Viable cells were counted in a haemocyt-
ometer using trypan blue exclusion and centrifugated, and the
cell pellets were resuspended with the medium. Approxi-
mately 5 x 106 viable cells per 0.2 ml of the medium were
injected into the mammary fat pad (two injections per mouse)
of4-week-old BALB-c-nu/nu female athymic nude mice (Clea
Japan, Tokyo, Japan). Tumour volume was calculated as the
product of the largest diameter, the orthogonal measurement
and the tumour depth. Mean tumour volume was calculated
as the sum of the tumour volumes divided by the number of
tumours.
Measurement of PTHrP
The PTHrP concentration in the cultured media of KPL-3C
cells was measured by a two-site immunoradiometric assay
kit (Mitsubishi Petrochemical Co., Tokyo, Japan). A rabbit
anti-human PTHrP (50-83) polyclonal antibody and a
mouse anti-human PTHrP (1-34) monoclonal antibody
were used in this assay. Recombinant human PTHrP (1-
87) was used as the standard. The detection limit of the assay
was 0.5 pmol -1, and the coefficients ofintra- and interassay
variations were not higher than 7.5% for three different
concentrations of the PTHrP (1-87) (Ikeda et al., 1994). To
estimate the amount of PTHrP secretion from the KPL-3C
cells, the cells were washed twice with PBS after removal of
the culture medium. Fresh medium with or without the
addition of phorbol-12-myristate-13-acetate (PMA, Sigma
Chem. Co.), hydrocortisone (Sigma Chem. Co.), medrox-
yprogesterone acetate (MPA, Japan Upjohn Co., Tokyo,KPL-3C human breast cancer cell line
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Japan) or 22-oxacalcitriol (OCT, Chugai Pharmaceutical Co.,
Tokyo, Japan) was added, and the cells were incubated for
48 h. Stock solutions of the agent were prepared in dimethyl
sulphoxide (Sigma Chem. Co.) or ethanol, and the final
concentration was 0.1%. Control cells received an equal
volume of the vehicle. Next, the medium was collected and
centrifugated at 1500 g for 10 min to spin down floating cells.
Then, the concentration of PTHrP in the supernatant was
measured. Because the concentration of PTHrP in the fresh
medium was undetectable and increased linearly for at least 5
days (data not shown), the PTHrP secretion into the medium
was defined as follows:
secrection per cell per 48 h=
concentration of PTHrP x volume of medium
mean cell number
Radiographic analysis
The transplanted KPL-3C tumours were resected, fixed with
5% buffered formalin and embedded in paraffin. The
paraffin-embedded specimens were radiographed with a
Softex type K-2 X-ray machine (Softex Co., Chiba, Japan).
Kodak X-Omat TL X-ray films (Eastman Kodak Co.,
Rochester, NY, USA) were used and developed with a Fuji
Medical Film Processor FPM-800 (Fuji Film, Tokyo, Japan).
The radiographic conditions were as follows: voltage, 20 KV;
electric current, 20 mA; exposure time, 12 s.
Results
Morphologicalfeatures
Each KPL-3C cell in culture is polygonal and possesses a
large nucleus with either a single prominent nucleolus or a
few prominent chromocentres. The cells tend to pile up on
each other and produce irregular-shaped colonies (Figure la).
The addition of PMA into the medium drastically alters the
growth property of the cells. The cells then become flat and
grow in a monolayer fashion like cobblestones (Figure lb).
Histological examination of the transplanted KPL-3C
tumours revealed that demarcated tumours formed in the
mammary fat pad of the nude mice and showed an expansive
growth. The tumours basically showed a solid structure, but
the tumour cells sometimes produced a large nest associated
with a central necrosis, resembling a comedo type of
intraductal breast cancer (Figure 2a). Interestingly, deposi-
tion of microcalcifications was frequently observed in the
central necrosis. The deposition was also observed in the
ductal structures beside the tumours, which appeared to be
lymphatic vessels (Figure 2b). Each tumour cell had a round
or oval-shaped large nucleus with a large nucleolus.
Histological examination of the original tumour of the
patient revealed a predominant intraductal component
associated with a massive central necrosis (Figure 2c) and
some invasive expansion into the stroma. The morphological
features of the original tumour of the patient are similar to
those of the transplanted KPL-3C tumours.
Ultrastructurally, a large oval or irregular-shaped nucleus
with a prominent chromatin and a typical intracytoplasmic
lumen was observed in the KPL-3C cells transplanted into
nude mice (Figure 3a). These findings are consistent with
cancer cells. In the cytoplasm, many mitochondria and well-
developed rough endoplasmic reticulum were recognised. In
addition, numerous intermediate filaments were observed at
the perinuclear region. Occasionally, junctional structures
among the tumour cells were seen (Figure 3b). These
structures are common in epithelial cells.
Immunohistochemical studies showed that the tumour
cells in the original tumour of the patient and the KPL-3C
cells transplanted into nude mice coincidentally expressed
cytokeratin, carcinoembryonic antigen, EMA and CA 15-3,
Figure 1 Phase-contrast microphotographs of KPL-3C cells in
culture. (a) The cells tending to pile up on each other and form an
irregular-shaped colony (original magnification x 50). (b) The
addition of 1OnM PMA to the culture medium causing the cells to
become flat and grow in a monolayer fashion (original, x 50).
but not vimentin and c-erbB-2 oncoprotein. These morpho-
logical findings suggest that the KPL-3C cells are of an
epithelial origin and are derived from the tumour cells of the
patient.
Because the mouse monoclonal antibody against recombi-
nant human PTHrP (1-34) used in this study cross-reacted to
mouse stromal cells, the expression ofPTHrP in KPL-3C cells
was not clearly demonstrated in the transplanted tumours. On
the other hand, the expression of PTHrP in cultured KPL-3C
cells was clearly demonstrated (Figure 4). The immunoreac-
tion was observed in the cytoplasm of KPL-3C cells.
Karyotype analysis
A total of 50 KPL-3C cells at the 8th or 35th passages were
studied, and a detailed analysis by the trypsin method was
performed in ten metaphases. The median chromosomal
number was 66 with a range from 60-67 at the 8th passage
and 64 with a range from 58-66 at the 35th passage. When
G-banding was performed, 18-21 marker chromosomes were
found at the 8th passage, and 19-24 at the 35th passage. The
common chromosomal aberrations at both passages were
lq+, 3p+, 8p+, 12p-, 12p+, 13q+, 14q+, 17p- and l9q+.
Chromosomes number 22 and X were not identified in either
passage (Figure 5). These findings suggest that this cell line is
derived from a monoclonal human cancer cell and that its
karyotype is relatively stable through the serial passages.
Receptor analysis and oncogene amplification
A small amount of ER and PgR was detected in the cultured
KPL-3C cells or in the transplanted KPL-3C tumours by the
enzyme immunoassay. The amount of ER and PgR was
15.3+0.2 and 14.0+2.5 fmol mg-' protein respectively
(mean+s.d., n= 3 each).KPL-3C human breast cancer cell line
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Figure 3 Electron microscopic findings of KPL-3C cells
transplanted into nude mice. (a) Electron micrograph showing a
tumour cell with a large hyperchromatic nucleus and an
intracytoplasmic lumen (original magnification x 4000). (b)
Electron micrograph showing a junctional structure (desmo-
some) between the tumour cells (original magnification x 40000).
Figure 2 Light microscopic findings of haematoxylin and eosin
stained sections of the transplanted KPL-3C tumours and of the
original tumour of the patient. (a) Transplanted KPL-3C cells
forming a round-shaped cluster and necrosis associated with the
deposition of microcalcifications (arrow) (original magnification
x 30). (b) Microcalcifications in the ductal structures beside a
transplanted KPL-3C tumour (arrows) (original magnification
x 150). (c) Original tumour cells of the patient showing a
predominant intraductal spread with massive central necrosis
and microcalcification (arrow) (original magnification x 75).
No gene amplification of c-erbB-2, H-ras and K-ras
measured by DNA dot-blot hybridisation was seen in
KPL-3C cells. The estimated copy number of the genes was
1.01 for c-erbB-2, 1.51 for H-ras and 1.16 for K-ras.
Cell growth in vitro and in vivo
The population doubling time of the KPL-3C cells was
approximately 72 h when the cells grew exponentially in
RPMI-1640 medium supplemented with 10% FBS. To
investigate tumorigenicity, KPL-3C cells at the 5th, 15th,
29th and 40th passages were injected into the mammary fat
pad of female athymic nude mice. The cells from the 5th and
15th passages did not develop tumours at all (0/6 for the 5th
passage and 0/12 for the 15th passage). However, the cells
from the 29th and 40th passages developed tumours at a take
rate of 100% (12/12 for the 29th passage and 10/10 for the
40th passage). The transplanted tumours grew slowly and the
tumour doubling time was approximately 1 week. The mean
volume of the tumours 6 weeks after the injections was
103 mm3 with a range of 24-225 mm3 for the 29th
passage.To investigate PTHrP secretion in vivo and bone
metastasis from KPL-3C cells, serum Ca2+ of mice bearing
transplanted KPL-3C cells are measured, and excised
vertebral bones at autopsy were radiographed with an X-
ray machine. Neither hypercalcaemia nor osteolytic changes
in the bones was observed. The size of the transplanted
tumours may be too small to increase a blood concentration
of PTHrP in nude mice. Because a mouse anti-human PTHrP
antibody was used in the PTHrP assay, mouse serum PTHrP
levels were unable to be measured.
Secretion of PTHrP
First, to investigate stable secretion of PTHrP from the KPL-
3C cells, the concentrations of PTHrP in the cultured media
of the cells at various passages were repeatedly measured by
the immunoradiometric assay as described above. Approxi-
mately 8 fmols per 106 cells per 48 h of PTHrP have been
constantly secreted from the cells at various passages (data
not shown).AMIM KPL-3C human breast cancer cell line
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Figure 4 Immunocytochemical analysis of KPL-3C cells in
culture. Paraffin sections cut from the samples were processed
by the immunoperoxidase procedure using anti-PTHrP mono-
clonal antibody as described in Materials and methods. (a)
Positive immunostaining in the cytoplasm (original magnification
x 300). (b) The negative control (original magnification x 300).
Second, since it has been reported that the secretion of
PTHrP from the BEN cell line, which is derived from human
lung cancer, is drastically stimulated by the addition of a
phorbol ester to the culture medium (Deftos et al., 1989), we
studied the effect of PMA on the secretion of PTHrP from
KPL-3C cells. Aliquots of 0.01 nM to 100 nm of PMA
significantly stimulated the secretion of PTHrP from KPL-3C
cells (Figure 6, P<0.01 in all comparisons between the
control and the treated groups). In addition, to examine the
inhibitory effect of steroid hormones on PTHrP secretion
from KPL-3C cells, three different steroid hormones were
added to the culture medium. An aliquot of 0.01 gUM of
hydrocortisone significantly increased PTHrP secretion but
1 lM significantly decreased the secretion. In contrast,
0.1 uM-10uM of MPA and 1 nM-100nM of OCT
decreased PTHrP secretion in a dose-dependent manner
(Figure 6).
These findings suggest that PTHrP secretion from KPL-3C
cells is stable through serial passages and regulated by the
addition of a phorbol ester or steroid hormones to the culture
medium.
Microcalcifications in the transplanted tumours
When KPL-3C cells transplanted into nude mice were
microscopically observed, there were a number of micro-
calcifications both inside and beside the tumours as described
above. To confirm that they were calcified substances, the
resected specimens were radiographed with an X-ray
machine. Interestingly, fine, dense and linear or irregular-
shaped microcalcifications were observed in each tumour
(Figure 7). These radiographic findings suggest that the
microcalcifications of the transplanted tumours are very
similar to those commonly observed in human breast
cancer. Three transplanted tumours injected with other cell
lines (MCF-7, MKL-4 or KPL-1) (Soule et al., 1973;
Kurebayashi et al., 1993 1995) were also radiographed by
the same method. No such microcalcifications were observed
in those tumours.
Figure 5 Representative Giemsa-banded karyotypes of the KPL-3C cell line at the eighth passage. Chromosome preparation and
staining are described in Materials and methods. Arrows indicate abnormal chromosomes. A total of 14 unidentified chromosomes
(marker chromosomes) were observed in this analysis.KPL-3C human breast cancer cell line
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Figure 6 Results of representative experiments to investigate the
effects of PMA and steroid hormones (HC, hydrocortisone; MPA,
medroxyprogesterone acetate; OCT, 22-oxacalcitriol) on PTHrP
secretion from KPL-3C cells in vitro. The PTHrP secretion was
calculated as described in Materials and methods. Values
represent the mean percentages of control. Bars show s.d.
Statistically significant secretion compared with control was
determined by Student's t-test: *P<0.05; **P<0.01.
Figure 7 Radiographic examination of KPL-3C tumours and
MKL-4 tumours transplanted into nude mice. The paraffin-
embedded samples were radiographed with an X-ray machine. A
number of microcalcifications were observed in each KPL-3C
tumour (upper part, five tumours) but not in the MKL-4 tumours
(lower part, three tumours).
Discussion
Well-characterised cancer cell lines are powerful research
resources not only for studying cancer cell biology but also
for studying cell biology in general. A number of breast
cancer cell lines have been contributing greatly to the
understanding of breast cancer cell biology and the
development of new therapeutic strategies against breast
cancer. To establish a new breast cancer cell line, we isolated
atypical epithelial cells from the pleural effusion of a breast
cancer patient with humoral hypercalcaemia and have been
maintaining the cells for over 2 years. Morphological analysis
using light and electron microscopes, cytogenetic analysis and
immunocytochemical analysis as described in Results suggest
that the KPL-3C cell line originates from a monoclonal
human breast cancer cell. In particular, a remarkable
coincidence of the expression of several immunocytochemical
markers by the original tumour cells of the patient and the
KPL-3C cells transplanted into nude mice indicates that
KPL-3C cells are derived from the tumour cells of the
patient. To the best of our knowledge, this KPL-3C cell line
is the first breast cancer cell line derived from a patient with
humoral hypercalcaemia.
It has been reported that a variety of human and animal
malignancies produce and secrete PTHrP (Ellison et al., 1975;
Strewler et al., 1983; Sato et al., 1987; Merryman et al., 1989;
Miyake et al., 1991; De Miguel and Esbrit, 1992; Ichinose et
al., 1993; Tabuenca et al., 1995; Birch et al., 1995). Although
immunohistochemical and molecular analyses clearly demon-
strate that the majority of breast cancer cells express PTHrP
in primary tumours and metastatic sites and, in particular, in
bone metastasis (Southby et al., 1990; Powell et al., 1991;
Bundred et al., 1992; Vargus et al., 1992; Bouizar et al., 1993;
Kohno et al., 1994a,b), only a little experimental data have
been published so far concerning PTHrP secretion from
established breast cancer cell lines (Tabuenca et al., 1995;
Birch et al., 1995). Preliminary results in the present study
suggest that the KPL-3C cell line constantly secretes a
detectable amount of PTHrP, and that this secretion is
stimulated by the addition of a phorbol ester to the culture
medium. Further analysis is underway to characterise the
molecular nature and biological activities of the immunor-
eactive PTHrP secreted from KPL-3C cells.
Microcalcifications in benign and malignant breast
diseases have been intensively explored by a large number
of researchers for earlier and more accurate diagnosis of
breast cancer (Egan et al., 1980; Sickles, 1986; Skinner et al.,
1988; De Lafontan et al., 1994). However, the mechanisms
that lead to the deposition of microcalcifications in breast
cancer remain unresolved. Recent studies suggest that the
expression of bone sialoprotein or PTHrP in breast cancer
cells may promote the deposition (Bellahcene et al., 1994;
Kanbara et al., 1993). Preliminary results in the present study
revealed that KPL-3C cells, which constantly secrete PTHrP
in vitro are tumorigenic in female nude mice and that there
are a number of microcalcifications in the transplanted
tumours. Moreover, the radiographic features of the
microcalcifications in the tumours are very similar to those
of typical microcalcifications in human breast cancer. Such
microcalcifications in the transplanted tumours seem to be
uncommon when other breast cancer cell lines are injected
into nude mice. These findings suggest that the secretion of
PTHrP from KPL-3C cells in vivo might induce the
deposition of microcalcifications in the transplanted tu-
mours. Further studies, such as a study on the influence of
steroid hormones on the deposition of microcalcification in
vivo, are needed to elucidate the detailed action mechanisms
of PTHrP that induce the deposition of microcalcifications.
Humoral hypercalcaemia are relatively common events in
patients with advanced malignancies. This causes a series of
deleterious problems including disturbance of the central
nervous and gastrointestinal systems. Subsequently, this
worsens the performance status and quality of life in the
patients with advanced malignancies (Martin, 1988; Mundy,
1990). Recently, newly developed agents, such as bispho-
sphonate, which decrease the osteolytic activity ofosteoclasts,
have been used clinically for malignancy-associated hypercal-
caemia caused by multiple osteolytic metastases or a high
blood level of PTHrP secreted by malignancies (Body et al.,
1986, 1989; Dumon et al., 1991). However, it has been
suggested that those agents are less effective against PTHrP-
induced hypercalcaemia than against that caused by multiple
bone metastases (Body et al., 1993; Walls et al., 1994). The
inhibition of PTHrP secretion from the malignancies seems to
be more effective against PTHrP-induced hypercalcaemia.
Recently, 1,25-dihydroxyvitamin D3 and its derivatives have
been reported to decrease the production and secretion of
PTHrP at the transcriptional level in normal or transformed
human keratinocytes, in human T cell lymphotrophic virus-
infected cell lines and normal mammary epithelial cells
(Kremer et al., 1991; Henderson et al., 1991; Inoue et al.,
1993; Sebag et al., 1994). Our preliminary data suggest that
hydrocortisone, MPA and a dihydroxyvitamin D3 analogue,
OCT, also significantly suppress PTHrP secretion from KPL-
3C human breast cancer cells in vitro (Figure 6). Although a
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low dose of hydrocortisone seemed to stimulate PTHrP
secretion by KPL-3C cells. further studies on mRNA.
processing and degradation of PTHrP are needed to clarify
this phenomenon.
In conclusion. a new human breast cancer cell line. KPL-
3C. which was derived from a patient with HHM. was
established. Preliminary characterisation revealed that this
cell line stably secretes immunoreactive PTHrP. The PTHrP
secretion is stimulated by a phorbol ester and suppressed by
steroid hormones. Interestingly, histological and radiographic
examinations revealed that microcalcifications in the trans-
planted tumours are similar to those commonly observed in
human breast cancer. These results suggest that this novel
breast cancer cell line may be a useful model not only for
studying the mechanisms that lead to microcalcifications in
breast cancer but also for investigating the regulatory
mechanisms of PTHrP secretion.
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